Intracranial Pressure Monitoring Devices Market is estimated to be valued at USD 1,532.8 Million in 2021 and is poised to grow at a significant CAGR of 6.9% over 2022-2028. Intracranial pressure monitoring (ICP) is a diagnostic procedure that assists doctors in determining if high or low cerebrospinal fluid (CSF) pressure is causing symptoms. The pressure in the head is measured directly using a tiny pressure-sensitive probe introduced through the skull. ICP is calculated in two methods. A short, hollow tube (catheter) is inserted into the fluid-filled area in the brain (ventricle), or an open device (bolt) is inserted through the skull into the region immediately between the skull and the brain. The growing frequency of neurological illnesses and severe accidents are pushing the intracranial pressure monitor market. The invasive techniques segment is anticipated to grow at a significant CAGR over the forecast years owing to invasive ICP measurements may be conducted at a variety of intracranial anatomical regions (i.e., intraventricular, intraparenchymal, epidural, subdural, and subarachnoidal). Furthermore, an cryoablation catheter connected to an external pressure transducer is the gold standard for continuous ICP monitoring, according to the Department of Clinical Neurosciences. This approach has been proven to be the most accurate and low-cost way for ICP monitoring, and it may also be utilized for therapeutic CSF draining and medication delivery. External ventricular drain and micro-transducer ICP monitoring are the two types of invasive procedures now in use. The Intracranial Pressure Monitoring Devices market is seeing increased product demand for a variety of reasons. One of the primary reasons driving the growth of the Intracranial Pressure Monitoring Devices market is the increasing number of road traffic injuries and associated trauma cases, the rising number of individuals suffering from traumatic brain injury (TBI), increasing prevalence of autoimmune, cardiovascular, and sleep disorders has catalysed the demand for ICT monitors to provide early and effective treatment.
Recent Market Developments:
In May 2019, The FDA has issued a class I recall for Integra LifeSciences LimiTorr Volume Limiting Cerebrospinal Fluid (CSF) Drainage System and its MoniTorr Intracranial Pressure (ICP) External CSF Drainage and Monitoring Systems.